Updating results

106 results

Sort: Relevance | Date

Abdominal aortic aneurysm

Proposed [GID-QS10035] Expected publication date: TBC

Quality standard Proposed

Depression in adults (update)

Proposed [GID-QS10057] Expected publication date: TBC

Quality standard Proposed

Secondary care management of malignant hypertension

Proposed [GID-QS10107] Expected publication date: TBC

Quality standard Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Managing symptoms with an uncertain cause

Proposed [GID-QS10103] Expected publication date: TBC

Quality standard Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Prevention of dementia

Proposed [GID-QS10109] Expected publication date: TBC

Quality standard Proposed

Thyroid disease

Proposed [GID-QS10088] Expected publication date: TBC

Quality standard Proposed

Nutrition in hospital

Proposed [GID-QS10104] Expected publication date: TBC

Quality standard Proposed

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Readmission to ICU within 48hrs

Proposed [GID-QS10105] Expected publication date: TBC

Quality standard Proposed

Road safety

Proposed [GID-QS10111] Expected publication date: TBC

Quality standard Proposed

Primary hyperparathyroidism

Proposed [GID-QS10089] Expected publication date: TBC

Quality standard Proposed

Spatial planning

Proposed [GID-QS10112] Expected publication date: TBC

Quality standard Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Proposed [GID-TA10612] Expected publication date: TBC

Technology appraisal guidance Proposed

Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

Proposed [GID-TA10566] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating severe eosinophilic asthma [ID3750]

Proposed [GID-TA10622] Expected publication date: TBC

Technology appraisal guidance Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: 16 December 2020

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: 24 March 2021

Technology appraisal guidance Proposed

Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Technology appraisal guidance Proposed

Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Technology appraisal guidance Proposed

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Proposed [GID-QS10106] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Sleep disordered breathing

Proposed [GID-QS10096] Expected publication date: TBC

Quality standard Proposed

Mental well-being: life course, settings and subgroups

Proposed [GID-QS10118] Expected publication date: TBC

Quality standard Proposed

Heat wave planning

Proposed [GID-QS10116] Expected publication date: TBC

Quality standard Proposed

Natural environments

Proposed [GID-QS10119] Expected publication date: TBC

Quality standard Proposed

Non-antibiotic clinical management of infectious diseases

Proposed [GID-QS10120] Expected publication date: TBC

Quality standard Proposed

Gambling

Proposed [GID-QS10099] Expected publication date: TBC

Quality standard Proposed

Programme management: effective ways to run public health programmes to generate a change in behaviour

Proposed [GID-QS10122] Expected publication date: TBC

Quality standard Proposed

Transport and health

Proposed [GID-QS10123] Expected publication date: TBC

Quality standard Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed